Our study suggests that MeCP2 up‐regulated epithelial markers, such as E‐cadherin, and that MeCP2 knockdown in breast cancer cell lines increased mesenchymal biomarkers, such as Vimentin. This evidence concerns the gene CDH1 and breast carcinoma.